FIELD: immunology; allergology.
SUBSTANCE: method for the treatment of chronic spontaneous urticaria is proposed, including subcutaneous (hereinafter – s/c) administration to a patient who needs it of a dose from 24 mg to 240 mg of ligelizumab or its antigen-binding fragment during week 0, and then s/c at a dose from about 24 mg to about 240 mg every month (every 4 weeks), starting from week 4.
EFFECT: invention provides achievement of a stable response relatively to urticaria: assessment of urticaria severity HSS7 = 0 in week 12 or UAS7 = 0, and dermatological life quality index DLQI = 0-1 in weeks 4, 12, and 20, improvements in patients informing about appearance of angioneurotic edema persisted up to 52 weeks.
28 cl, 4 dwg, 9 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING BRUTON TYROSINE KINASE INHIBITOR | 2020 |
|
RU2818678C2 |
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2013 |
|
RU2690675C2 |
| METHODS FOR TREATING NASAL POLYPOSIS BY ADMINISTERING IL-4R ANTAGONIST | 2014 |
|
RU2674680C2 |
| METHODS OF TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2734490C2 |
| METHODS FOR THE TREATMENT OF ALLERGY AND INCREASING THE EFFICIENCY OF ALLERGEN-SPECIFIC IMMUNOTHERAPY BY INTRODUCING IL-4R INHIBITOR | 2014 |
|
RU2789047C2 |
| METHODS FOR INCREASING VACCINE EFFICIENCY BY INJECTING IL-4R ANTAGONIST | 2017 |
|
RU2753869C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING IL-4R ANTAGONIST | 2013 |
|
RU2666630C2 |
| METHODS FOR TREATING ALLERGY AND ENHANCING ALLERGEN-SPECIFIC IMMUNOTHERAPY BY ADMINISTERING IL-4R INHIBITOR | 2014 |
|
RU2679920C2 |
